RECORNEA

RECORNEA will be pitching at the Grand Finals of the EIT Health InnoStars Awards 2024 to be held on 27th November 2024 in Budapest as one of the 20 finalists in the validation track. We invite you to watch the event live and support us in preventing blindness through innovation. #ophthalmology #cornea #keratoconus

RECORNEA was selected as one of the top 20 finalists to receive the EIT Health InnoStars awards in the validation track. As part of the validation track, the CSO of Recornea, Dr. Moses Kakanga attends two bootcamps in Budapest and Warsaw as well as the Grand final for the EITHealth InnoStars awards in Budapest on 27th November, 2024. Attending the EITHealth InnoStars awards bootcamps will provide us with the opportunity connect with VCs willing to support our open seed round of 1.2 M€, of which 750 k€ has been obtained with 450 k€ remaining to close the seed round by the end of 2024. Attending the bootcamps will also provide us the opportunity to get insights on marketing strategies and updates in the EU regulatory requirements for medical devices. We thank EIT Health InnoStars for the great initiative to support the growth of our company. #ophthalmology #cornea #keratoconus

Follow us through our #newsletter ! We just released our newsletter for Q3-2024. If you are interested to receive it regularly every two months by email, PM Emiliano Lepore or Moses Kakanga. Stay tuned ! https://lnkd.in/dZfF7-Tb

RECORNEA is back home after a series of presentations and events in September where Emiliano Lepore, Co-founder and CEO, delivered two presentations about our activities and recent milestones at the #ophthalmologyfuturesforum in Barcelona, Spain and at LSI Europe 2024 in Sintra, Portugal, where 750 executives from emerging companies, venture capital and private equity firms, family offices, global strategics, professional service providers, convened all together to share experience and lessons learned along the way in the journey of developing new (and exciting) medical devices. A great achievement for the entire team of Recornea ! Moses Kakanga, Edoardo Grosso, Rossella Baldini, Letizia Mansutti, Paola Di Rosa, Thomas Nißl, Jennifer Nißl, Graziana Ragonese. #ophthalmology #cornea #keratoconus

As with all beautiful stories, the European project #HUMANeye was funded by the European Commission and it has recently come to an end. RECORNEA, as one of the consortium beneficieries, couldn't be more excited to share the successful results which have opened the way to groundbreaking advancements in vision correction with our revolutionary technology applied to our first product, the GROSSO® implant for keratoconus! This pioneering stent solution has the potential to transform the lives of countless individuals by offering a new hope for those with keratoconus and potentially other corneal issues. The journey has been incredibly rewarding, and we are proud to have contributed to such an innovative and impactful initiative. We thank the European Commission for the financial support and for having believed in our innovation. 👉 Discover more about this cutting-edge development and the journey from research to impactful results in the following article recently published by the European Commission: The pioneering vision-correcting cornea implant. 👉 Click here: https://lnkd.in/dZnBEfKN Our clinical journey is just starting ! Stay tuned for more updates as we continue to push the boundaries of medical technology and vision correction. #Innovation #MedicalTechnology #MedicalDevice #VisionCorrection #CorneaImplant #HealthcareRevolution #keratoconus #CORDIS #HUMANeye #ophthalmology #cornea

Follow us through our hashtag hashtag #newsletter ! We just released our newsletter for May and June 2024. If you are interested to receive it regularly every two months by email, PM Emiliano Lepore or Moses Kakanga. Stay tuned ! https://lnkd.in/dUz9Ngcw

It was 5 years ago when Moses Kakanga and I decided to start our MedTech company RECORNEA in Singapore.   We started two people with one idea from Dr. E. Grosso, one investor, one dream “Preventing blindness through innovation”. That dream was persistent and recurring to a point that brought us and our company to move to a different continent from Asia to Europe, to have 7 new amazing people joining our team, to bring 6 new investors onboard, to reach the clinical phase for our first-line medical device, the GROSSO Implant for the treatment of keratoconus, to turn a product-oriented company into a proprietary platform technology expanding it to 3 new products in the pipeline and have 22+ key opinion clinical leaders believing in our company.   Our journey as co-founders and as a company had a lot of ups and downs which didn’t defocus us from our clear goal but helped us to refine the strategy for efficient execution with a great feeling of satisfaction and excitement for each and single step we were able to accomplish.   We thank our growing team members, clinicians, collaborators, partners, investors and supporters in general who believe in us, in our expertise and vision to achieve such ambitious goals while we were building a MedTech company.   Stay tuned to see how and where we will be in next 5 years from now !

Follow us through our hashtag #newsletter ! We just released our newsletter for March and April 2024. If you are interested to receive it regularly every two months by email, PM Emiliano Lepore or Moses Kakanga. Stay tuned ! https://lnkd.in/dUKsnjQb

We are very pleased to have on board Dr. Letizia Mansutti, MD, Ophthalmic Surgeon, Angel Investor and Board Member in RECORNEA. She has main focus on refractive surgery, cataract and lasers, but she is a very special ophthalmologist, because she supported humanitarian initiatives and says “the philosophy of give-back is deeply rooted in me”. And more: “I am passionate about the world of innovation”. As an angel investor, she supports companies in the health, wellness, nutrition, and non-profit sectors. She is dedicated to investing in high-impact startups that improve the world we live in. Her mission is to help people live healthier, happier, and longer lives while championing a sustainable planet. She is an enthusiast of supporting creative and visionary young people. Letizia shares her long expertise in ophthalmology helping Recornea to support the planning, approvals and execution of the pre-clinical and clinical activities, promote and communicate about the products of the Company e.g. in public speeches, with investors, etc.. and assist the company in the process of innovation for new medical devices for treating other diseases in the field of ophthalmology. #ophthalmology #cornea #keratoconus #nitinol

Exciting News Alert !! We are thrilled to announce that we have received regulatory approvals to conduct the First in Human Clinical Trial with our first-line medical device for the treatment of keratoconus in Spain. Thus, Recornea is entering the clinical phase in humans. This marks a significant milestone in our journey toward bringing innovative healthcare solutions to patients who suffer from this disease and for whom no treatment other than transplantation is currently envisaged. Our team worked tirelessly and we could not be more proud to have achieved this result. This achievement underscores our commitment to advancing medical research and preventing blindness through innovation. The First in Human trial will be an essential step in evaluating the safety and efficacy of our GROSSO® Implant in human subjects towards the CE certification. We are excited to take this important next step and look forward to sharing updates as the trial progresses. A heartfelt thank you to everyone who has supported us along the way – our partners, collaborators, investors, and, most importantly, the patients who inspire us every day. Together, we are making a difference in the lives of patients worldwide. Stay tuned for more updates on our First in Human trial journey! #ClinicalTrials #MedicalInnovation #FirstInHuman #Healthcare #MedicalDevice #ophthalmology #cornea #keratoconus